| Autor: |
Román, Alejandra Romero, Cruz, Jose Luis Campo-Cañaveral de la, Macía, Iván, Campuzano, Ignacio Escobar, Almánzar, Santiago Figueroa, Roel, María Delgado, Muñoz, Carlos Gálvez, Fontán, Eva M García, Trueba, Ignacio Muguruza, Vielva, Laura Romero, Garcia, José Ramón Cano, Téllez, Elisabeth Martínez, González, Concepción Partida, López, Marcelo Fernando Jiménez, Maestre, Unai Jiménez, Poce, Roberto Mongil, Lorente, David Sánchez, Kindelán, Antonio Álvarez, Pulla, Mariano Provencio |
| Předmět: |
|
| Zdroj: |
European Journal of Cardio-Thoracic Surgery; Jul2021, Vol. 60 Issue 1, p81-88, 8p |
| Abstrakt: |
Open in new tab Download slide Open in new tab Download slide OBJECTIVES This analysis aimed to evaluate perioperative outcomes of surgical resection following neoadjuvant treatment with chemotherapy plus nivolumab in resectable stage IIIA non-small-cell lung cancer. METHODS Eligible patients received neoadjuvant chemotherapy (paclitaxel + carboplatin) plus nivolumab for 3 cycles. Reassessment of the tumour was carried out after treatment and patients with at least stable disease as best response underwent pulmonary resection. After surgery, patients received adjuvant treatment with nivolumab for 1 year. Surgical data were collected from the NADIM database and patient charts were reviewed for additional surgical details. RESULTS Among 46 patients who received neoadjuvant treatment, 41 (89.1%) underwent surgery. Two patients rejected surgery and 3 did not fulfil resectability criteria. There were 35 lobectomies (85.3%), 3 of which were sleeve lobectomies (9.4%), 3 bilobectomies (7.3%) and 3 pneumonectomies (7.3%). Video-assisted thoracoscopy was the initial approach in 51.2% of cases, with a conversion rate of 19% (n = 4). There was no operative mortality at either 30 or 90 days. The most common complications were prolonged air leak (n = 8), pneumonia (n = 5) and arrhythmia (n = 4). Complete resection (R0) was achieved in all patients who underwent surgery, downstaging was observed in 37 patients (90.2%) and major pathological response in 34 patients (82.9%). CONCLUSIONS Surgical resection following induction therapy with chemotherapy plus nivolumab appears to be safe and offers appropriate oncological outcomes. Perioperative morbidity and mortality rates in our study were no higher than previously reported in this setting. A minimally invasive approach is, therefore, feasible. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
